An Omega-3 related acquisition was a tasty treat for some shareholders Friday, while a Health Canada ruling boosted a pharma stock. Here’s some small stocks making big moves on Friday, January 8, 2016 (as of 11:30 am EST):
Neptune Technologies & Bioressources Inc. (TSX: NTB) shares powered 25% higher to $1.67 on Friday after the biotechnology company announced that it has acquired privately-held Biodroga Inc. for C$15 million in a combination of cash and stock. Biodroga is a solution provider of omega-3’s and other functional ingredients to branded marketers in the nutraceutical industry, and has trailing 12-month revenues of C$22 million.
As well, shares of Acerus Pharmaceuticals Corporation (TSX: ASP) gained 13% to $0.17 as the Canadian pharmaceutical company said Health Canada has approved NATESTO, the first and only nasal gel for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).
KGIC Inc. (TSXV: LRN), meanwhile, reported that it has entered into a strategic relationship with Guru Kashi University and BIS Education Group by way of a memorandum of understanding for providing ESL education services to its student bodies, which exceeds 150,000 students on 28 campuses in India. KGIC stock moved up 40% to $0.035 on volume of more than 10.5 million shares following the announcement.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me at sean@smallcappower.com.
DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source.
